Agios Pharmaceuticals (AGIO) Q2 2024 earnings summary

Executive summary

• Achieved multiple milestones in Q2 2024, including positive Phase 3 data for mitapivat in thalassemia and pediatric PK deficiency, and a $905 million royalty purchase agreement for vorasidenib, with total potential payments of $1.1 billion upon FDA approval.

• PYRUKYNDⓇ net revenue reached $8.6 million in Q2 2024, up from $6.7 million in Q2 2023, driven by increased patient demand and commercial expansion.

• Commercial partnerships and distribution agreements established for PYRUKYNDⓇ in the GCC region, with Saudi FDA Breakthrough Medicine Designation.

• Net loss for Q2 2024 was $96.1 million, up from $83.8 million in Q2 2023, reflecting higher R&D and SG&A expenses.

• Maintains strong cash, cash equivalents, and marketable securities position of $645.3 million as of June 30, 2024.

Financial highlights

• Q2 2024 PYRUKYNDⓇ net revenue was $8.6 million, up $1.9 million year-over-year and 5% sequentially.

• R&D expenses rose to $77.4 million, and SG&A expenses to $35.5 million in Q2 2024, both increasing year-over-year.

• Cost of sales for Q2 2024 was $1.5 million.

• Net loss per share for Q2 2024 was $(1.69), compared to $(1.51) in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $645.3 million as of June 30, 2024.

Outlook and guidance

• sNDA for mitapivat in thalassemia planned by end of 2024, aiming for a label covering all subtypes.

• Top-line data from ACTIVATE-Kids (non-transfused pediatric PKD) and RISE-UP (sickle cell) expected in 2025.

• Anticipates $1.1 billion in payments upon potential FDA approval of vorasidenib (PDUFA date: August 20, 2024), with a 3% royalty on U.S. net sales above $1 billion.

• Cash and anticipated payments expected to support launches and pipeline expansion for at least the next twelve months.

• Expects U.S. approval for PYRUKYNDⓇ in thalassemia in 2025 and in sickle cell disease in 2026.